FATİH GÜLÇEBİ

Dr. FATİH GÜLÇEBİ

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Echocardiography
Verified
Journal Article
Closed access
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
AÖAhmet Özderya
Ahmet Özderya
İDİsmet Durmuş
İsmet Durmuş
MSMuhammet Raşit Sayın
Muhammet Raşit Sayın

3 August 2026 in Indian Pacing and Electrophysiology Journal
Verified
Journal Article
Open access
SASedat Altıntepe
Sedat Altıntepe
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
AÖAhmet Özderya
Ahmet Özderya
NBNurel Bellur
Nurel Bellur
EKEzgi Kalaycıoğlu
Ezgi Kalaycıoğlu

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AÖAhmet Özderya
Ahmet Özderya
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
MMMehmet Ali Maz
Mehmet Ali Maz
SŞSinan Şahin
Sinan Şahin
MSMuhammet Raşit Sayın
Muhammet Raşit Sayın
OBJECTIVE: Cardiac implantable electronic devices are widely used today. Therefore, research is ongoing to provide better device implantation in technical terms. The aim of this study was to investigate the relationship between pre-procedural regional right ventricular strain and post-procedural endocardial R-wave amplitude in patients scheduled to receive an implantable cardiac defibrillator.

16 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
AÖAhmet Özderya
Ahmet Özderya
AKAli Hakan Konuş
Ali Hakan Konuş
MMMehmet Ali Maz
Mehmet Ali Maz
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
AAAli Rıza Akyüz
Ali Rıza Akyüz
Background and Objectives: Transcatheter aortic valve replacement (TAVR) has become an established treatment for severe symptomatic aortic stenosis, and continuous technological advances have led to the development of different transcatheter heart valve (THV) systems. This study aimed to compare the short- and mid-term clinical outcomes of the balloon-expandable Myval (Meril Life Sciences, India) and the self-expanding Acurate Neo (Boston Scientific, MA, USA) transcatheter heart valves during a mean follow-up of 18 months. Materials and Methods: This retrospective single-center study included consecutive patients who underwent transfemoral TAVR with either the Myval or Acurate Neo valve between January 2020 and September 2022. Demographic, clinical, laboratory, electrocardiographic, echocardiographic, procedural, and follow-up data were collected and compared. Clinical outcomes were evaluated according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: A total of 147 patients were included (Myval, n = 116; Acurate Neo, n = 31). Predilatation was performed in all patients in the Acurate Neo group but in only 22 (18.9%) patients in the Myval group (p < 0.001). In-hospital mild paravalvular leak (PVL) was more frequent in the Acurate Neo group (38.7% vs. 20.6%; p = 0.038), whereas moderate or greater PVL did not differ between the groups. During a mean follow-up of 18 months (range, 10–32 months), mild PVL remained significantly more frequent in the Acurate Neo group (p = 0.028). No significant differences were observed between the two valve systems regarding mortality, permanent pacemaker implantation, or other major VARC-3 clinical outcomes. Conclusions: The Myval and Acurate Neo transcatheter heart valves demonstrated comparable short- and mid-term clinical outcomes in patients undergoing TAVR. Although mild PVL was more frequent with the Acurate Neo valve, mortality, permanent pacemaker implantation, and moderate or greater PVL were similar between the two valve systems, supporting the safety and effectiveness of both prostheses in the treatment of severe symptomatic aortic stenosis.

1 August 2025 in Kosuyolu Heart Journal
Verified
Journal Article
Open access
PDF file
AÖAhmet Özderya
Ahmet Özderya
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
EAERCAN AYDIN
ERCAN AYDIN
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
AAAli Rıza Akyüz
Ali Rıza Akyüz
Objectives: To examine the association between the presystolic wave (PSW), an echocardiographic parameter indicative of diastolic dysfunction (DD), and the electrocardiographic diastolic index (EDI), which is calculated using 12-lead electrocardiography (ECG), in hypertensive cases. Methods: The study included 250 consecutive patients diagnosed with hypertension, evaluated in two groups: According to PSW presence. Statistical analyses were conducted to compare demographic data, laboratory parameters, and 12-lead ECG parameters between the groups with and without PSW. Results: PSW was found to be linked to advanced age (p<0.001), systolic blood pressure (p=0.045), diastolic blood pressure (p=0.020), fasting blood glucose (p=0.015), blood urea nitrogen (p=0.044), left ventricular wall thickness (p<0.001), mitral valve late diastolic wave (A wave, p=0.002), mitral valve early diastolic wave (E wave)/early diastolic myocardial wave (E’ wave) ratio (p<0.001), E/A ratio (p=0.031), AVL R amplitude (p=0.003), V1 S amplitude (p=0.020), V5 R amplitude (p=0.004), D1 P wave duration (p=0.017), PQ interval (p=0.011), QRS duration (p=0.015), and EDI (p<0.001). Age, A wave, and EDI (p<0.001) were found to independently predict PSW presence. Conclusion: We determined that, in addition to the echocardiographic assessment of PSW, EDI, an index that can be easily calculated using a 12-lead ECG, may also be a useful parameter for evaluating DD in hypertensive patients.